FDA Peptide Status 2026: Which Are Legal to Compound and Market?

This article is for educational purposes only and does not constitute legal advice. Regulations change frequently — consult a qualified attorney or compliance specialist before making decisions based on this content.

The regulatory landscape for peptide compounding shifted significantly across 2024–2026. For compounding pharmacies, telehealth providers, and the brands that market to them, understanding which peptides are currently legal to compound — and how to communicate about them — is no longer optional. It is the foundation of every compliant marketing decision you will make this year.

This guide breaks down the current FDA peptide compounding status by category, explains the legal framework behind those classifications, uses the GLP-1 compounding controversy as a live case study in how fast status can shift, and lists specific compliance requirements for marketing compounded peptides.

Key Takeaways: The FDA uses a three-category framework for compounded peptides under Section 503A. Category 1 peptides (Sermorelin, Ipamorelin, PT-141) can be marketed with confidence. Category 2 peptides (BPC-157, TB-500, GHK-Cu) are currently legal to compound but face an uncertain future — communicate status accurately. Category 3 peptides cannot be marketed through legitimate compounding channels. The GLP-1 compounding crisis demonstrates how quickly regulatory action can follow commercial scale-up.

The Legal Architecture: 503A vs. 503B

Before reviewing individual peptide status, it is essential to understand the two statutory frameworks that govern compounding in the US. They operate differently and create different obligations for pharmacies and the brands that market their services.

Section 503A: Traditional Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) governs traditional state-licensed compounding pharmacies. Under 503A, a licensed pharmacist may compound a drug for an identified individual patient pursuant to a valid, patient-specific prescription from a licensed practitioner.

For bulk drug substances — ingredients not themselves FDA-approved drugs — 503A pharmacies may only compound using substances that appear on the 503A Bulks List (substances the FDA has affirmatively approved for compounding) or that are Category 2 nominations under active review (substances in the queue but not yet decided). The nominal process works through public dockets where manufacturers, pharmacies, professional organizations, and practitioners submit nominations; the FDA evaluates each substance for clinical need, safety profile, and whether an FDA-approved alternative exists.

503A compounds are patient-specific. They cannot be prepared in advance, sold in bulk, or distributed without a prescription. This means marketing is properly directed at prescribing providers and potential patients seeking a provider, not at general consumer purchase.

Section 503B: Outsourcing Facilities

Section 503B governs FDA-registered outsourcing facilities — entities that may compound larger volumes and distribute to healthcare facilities and providers without individual patient prescriptions, but who operate under more stringent FDA oversight including Current Good Manufacturing Practice (cGMP) requirements and facility registration.

503B outsourcing facilities use a separate approved substance list. Some peptides eligible under 503A are also eligible under 503B; others are not. Importantly, 503B facilities face more frequent FDA inspection and may be subject to enforcement action that does not affect 503A pharmacies, and vice versa.

Key practical distinction: If a compounding pharmacy’s marketing implies broad distribution capability (e.g., selling to clinics in bulk, shipping across states without individual prescriptions), 503A status does not cover that. Understanding which framework applies to each business model is a foundational compliance question.

The Bulk Drug Substance Nomination Process

The pipeline of peptide regulatory decisions flows through a specific administrative process:

1. Nomination: Any interested party may submit a nomination to include a bulk substance on the 503A list via FDA’s public docket. Nominations must include safety and efficacy data, proposed medical use, and evidence that the compound cannot be replaced by an FDA-approved product.

2. Category Assignment: The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviews nominations and assigns them to Category 1 (recommend for inclusion), Category 2 (under review), or Category 3 (recommend against inclusion).

3. Public comment periods: PCAC recommendations are published in the Federal Register with comment periods. Practitioners, pharmacies, and patient groups can submit comments that may influence final determinations.

4. Final Rule: The FDA publishes a final rule amending 21 CFR Part 216 to add or exclude substances. This is the binding regulatory action that terminates Category 2 status and creates Category 1 or 3 status.

Category 2 status is, by design, transitional. When the FDA completes its evaluation, every Category 2 compound will become Category 1 or Category 3. The compounding sector should not treat “under review” as a permanent operating condition.

Current Peptide Status by Category (2026)

The table below reflects the most current publicly available FDA position on commonly compounded peptides. Compounding pharmacies should verify current status with their legal and compliance teams, as classifications can change with new FDA guidance.

Peptide	Common Name	Current Category	Compounding Status
Sermorelin	GHRH analog	Category 1	Legal — on 503A Bulks List
CJC-1295 (without DAC)	Mod GRF 1-29	Category 1	Legal — on 503A Bulks List
Ipamorelin	GHRP analog	Category 1	Legal — on 503A Bulks List
Tesamorelin	Egrifta analog	Category 1 (503B)	Legal (503B outsourcing; 503A blocked by RLD doctrine)
PT-141 (Bremelanotide)	Melanocortin agonist	Category 1	Legal — on 503A Bulks List
BPC-157	Body Protection Compound	Category 2	Under review — may be compounded pending final rule
TB-500 (Thymosin Beta-4)	Wound healing peptide	Category 2	Under review — may be compounded pending final rule
AOD-9604	GH fragment	Category 2	Under review
GHK-Cu	Copper peptide	Category 2	Under review
Epithalon	Telomerase activator	Category 3	Not eligible for 503A compounding
Selank	Anxiolytic peptide	Category 3	Not eligible for 503A compounding
Semax	Nootropic peptide	Category 3	Not eligible for 503A compounding

Note: This table is for informational purposes only. Regulatory classifications are subject to change. Consult a regulatory attorney or your state board of pharmacy before making compounding decisions based on this information.

Category 1: Peptides Legal to Compound in 2026

Category 1 peptides have been reviewed by the FDA and placed on the 503A Bulks List, meaning they can be compounded by licensed pharmacies for individual patient use pursuant to a valid prescription.

Sermorelin

Sermorelin is a 29-amino acid fragment of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and release growth hormone through natural feedback mechanisms, making it distinct from direct HGH administration.

Because sermorelin works through the hypothalamic-pituitary axis rather than bypassing it, growth hormone release remains pulsatile and subject to normal somatostatin counter-regulation. This is the basis for the clinical argument that sermorelin avoids the receptor desensitization associated with continuous exogenous GH. The mechanism that preserves pulsatility is sermorelin’s short half-life (~10–12 minutes): after subcutaneous injection, sermorelin achieves rapid GHRH-R occupancy on pituitary somatotrophs → Gs/cAMP/PKA → GH secretory granule exocytosis, producing a GH pulse. Within 15–20 minutes, sermorelin is degraded by circulating DPP-IV and tissue proteases, GHRH-R occupancy falls, and the Gs/cAMP signal terminates. Periventricular somatostatin neurons (which receive inhibitory feedback from rising IGF-1 generated by the GH pulse through a specific receptor mechanism: IGF-1 crosses the blood-brain barrier via LRP1 (low-density lipoprotein receptor-related protein 1)-mediated transcytosis at brain capillary endothelium → binds IGF-1R (IGF-1 receptor) on periventricular somatostatin neurons → IGF-1R autophosphorylation at Tyr1316 recruits PLCγ1 → PLCγ1 cleaves PIP₂ → IP₃ + DAG → IP₃ releases Ca²⁺ from ER in SST neuron axon terminals → Ca²⁺-dependent SNARE-mediated SST vesicle exocytosis; IGF-1R simultaneously activates IRS-2 → PI3K/Akt → MAPK/ERK1/2 → CREB → CRE-driven SST gene transcription sustaining the SST peptide pool for subsequent pulses — the complete short-loop negative feedback by which the liver’s IGF-1 output from each GH pulse reinstates hypothalamic somatostatinergic tone) then re-establish their tonic SST-R2/Gi inhibitory brake on somatotrophs — creating the inter-pulse trough. The next dose of sermorelin again temporarily overrides this SST brake, producing the next pulse. The physiological pulse-trough pattern is preserved because the GHRH-R occupancy is intrinsically time-limited. By contrast, continuous exogenous recombinant GH (or a very long-acting GHRH analogue given without dosing gaps) provides sustained circulating GH → sustained hepatic IGF-1 production → chronic negative feedback activating hypothalamic SST neurons → chronically elevated portal SST → prolonged Gi-mediated cAMP suppression in somatotrophs → progressive GH receptor (GHR) downregulation via JAK2/STAT5b-mediated transcriptional suppression of GHR gene expression. It is this chronic, unbraked IGF-1/SST feedback loop — absent with short-acting pulsatile sermorelin — that drives the receptor desensitization and metabolic side effects (insulin resistance, edema) at supraphysiologic exogenous GH doses.

Legal status: Category 1, eligible for 503A compounding.

Marketing implications: Sermorelin can be discussed in the context of legitimate medical prescribing through licensed providers. Telehealth platforms and clinics can include it in wellness programs. Marketing should reference the prescription requirement and individual medical evaluation clearly. Performance claims must be substantiated; general educational content about the mechanism is permissible.

CJC-1295 (without DAC)

CJC-1295 without DAC (Modified GRF 1-29) is a shorter-acting GHRH analog. Frequently combined with Ipamorelin in peptide therapy protocols, it stimulates GH pulses with a relatively short half-life, typically 30 minutes, which mirrors endogenous GHRH pulsatility more closely than longer-acting analogues. The 30-minute half-life — three times longer than sermorelin’s 10–12 minutes — results from four targeted amino acid substitutions in the native GHRH(1–29) sequence, the most critical of which directly blocks the DPP-IV degradation pathway that limits sermorelin. Native GHRH has histidine at position 1 and alanine at position 2 (His¹-Ala²); DPP-IV (dipeptidyl peptidase-4, the serine protease that cleaves GLP-1 at His⁷-Ala⁸ by the same mechanism) preferentially cleaves after the penultimate N-terminal residue when the second-position amino acid is unhindered — Ala² at the DPP-IV S1 pocket is the canonical recognition substrate. In sermorelin, Ala² is retained from native GHRH → DPP-IV cleaves His¹-Ala² within 2–4 minutes of injection → produces GHRH(3–29), which has negligible GHRH-R affinity because the N-terminal His¹ and Ala² residues are required for the peptide to insert into the receptor’s transmembrane domain binding pocket. Modified GRF 1-29 replaces Ala² with Aib (α-aminoisobutyric acid, 2-methylalanine): both α-carbons of Aib carry methyl groups (geminal dimethyl substitution), creating a steric bulk that physically occludes the S1 pocket of DPP-IV → DPP-IV cannot achieve the orientation required for its Ser630/Asp708/His740 catalytic triad to complete the hydrolysis reaction → the His¹-Aib² bond is DPP-IV-resistant. Three additional substitutions further stabilize the peptide: Gln⁸→Ala reduces susceptibility to glutaminyl cyclization (an asparagine-like cyclization of glutamine under physiological conditions that produces inactive pyroglutamyl derivatives); Ala¹⁵→His and Leu²⁷→Ala reduce protease susceptibility at internal sites. The combined result is a half-life extending from sermorelin’s 10–12 minutes to approximately 30 minutes — long enough to drive a discrete GH pulse while short enough for GHRH-R occupancy to terminate before the somatostatin counter-regulatory brake re-establishes its inter-pulse inhibition (the same mechanism described in the sermorelin section above that preserves physiological pulsatility). The CJC-1295 with DAC version builds on this 30-minute scaffold by adding the maleimide-albumin conjugation mechanism (described below), extending half-life from 30 minutes to 6–8 days — the two half-life tiers (30 min without DAC, 6–8 days with DAC) thus share the same Aib²-based DPP-IV resistance as a foundation, with the DAC modification layered on top for the ultra-long-acting version.

Legal status: Category 1, eligible for 503A compounding.

Marketing implications: The “with DAC” vs. “without DAC” distinction matters legally — and mechanistically. CJC-1295 with DAC contains a C-terminal Drug Affinity Complex modification: a reactive maleimide (Michael acceptor) electrophile conjugated to the peptide’s C-terminal lysine residue. After subcutaneous injection, this electrophilic group undergoes spontaneous nucleophilic addition with the free thiol group of Cys-34 on circulating human serum albumin (HSA) — the most abundant plasma protein at ~40 g/L — forming a semi-covalent thioether linkage. The resulting CJC-1295–albumin conjugate now circulates with albumin’s plasma half-life (~19 days), acting as a slow-release depot: gradual enzymatic hydrolysis of the thioether linker releases free GHRH-analog peptide over approximately 8 days. The pharmacological consequence is a continuous background of circulating GHRH-receptor agonist rather than the pulsatile 30-minute window of the unmodified peptide. This matters biologically: prolonged, tonic GHRH-R occupancy produces a continuous elevation of GH and IGF-1 rather than the discrete GH pulses of the unmodified compound. For the regulatory question, CJC-1295 with DAC’s extended half-life and different pharmacodynamic profile make it a meaningfully different compound — not a simple substitution.

The “with DAC” vs. “without DAC” distinction matters legally. CJC-1295 with DAC has a different regulatory status and is generally not considered equivalent to the without-DAC version for compounding purposes. Marketing must be precise about which compound is referenced.

Ipamorelin

Ipamorelin is a growth hormone-releasing peptide (GHRP) that selectively stimulates GH release with minimal effect on cortisol or prolactin — a selectivity profile that made it preferred in clinical protocols over earlier GHRPs like GHRP-2 and GHRP-6, which carry more off-target effects. Ipamorelin’s selectivity arises from its binding preference for ghrelin receptors (GHSR-1a) in a configuration that limits downstream ACTH/cortisol pathway activation. The molecular basis is biased agonism at GHSR-1a. GHSR-1a is a Class A GPCR that couples to both Gs (stimulatory) and Gq (phospholipase C-activating) subunits. Earlier GHRPs — GHRP-2 and GHRP-6 — activate both Gs and Gq subunits when they bind GHSR-1a. The Gs arm → adenylyl cyclase → cAMP → PKA → L-type Ca²⁺ channel phosphorylation → GH secretory granule exocytosis (the desired effect). The Gq arm → PLC-β → IP₃/DAG → IP₃ releases intracellular Ca²⁺ → DAG activates PKC → PKC in hypothalamic neurons activates CRH (corticotropin-releasing hormone) secretion → CRH reaches the anterior pituitary → ACTH release → adrenal cortisol production (the off-target effect). GHRP-2 and GHRP-6 produce significant cortisol and prolactin elevations in clinical subjects precisely because their binding conformation engages both Gs and Gq. Ipamorelin’s cyclic pentapeptide scaffold (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) binds GHSR-1a in a conformation that preferentially stabilizes the Gs-coupling interface while minimally engaging the Gq-coupling interface — a phenomenon called G-protein-biased agonism. With minimal Gq activation, PKC-mediated CRH secretion is greatly attenuated, and ACTH/cortisol are not significantly elevated. This biased agonism is the specific structural property that made ipamorelin the preferred GHRP in clinical GH-axis protocols despite its later development compared to GHRP-2 and GHRP-6.

Legal status: Category 1, eligible for 503A compounding.

Marketing implications: Typically marketed alongside CJC-1295 as a combination protocol. The combination takes advantage of complementary mechanisms — CJC-1295 provides GHRH-pathway stimulation while Ipamorelin blocks somatostatin’s inhibitory signal — a mechanism that operates through GHSR-1a’s simultaneous expression on periventricular nucleus (PeVN) somatostatin neurons in the hypothalamus, not just on pituitary somatotrophs. GHSR-1a on these hypothalamic SST neurons couples to Gαi/Gαo (in contrast to the Gαq-dominant coupling on somatotrophs) → adenylyl cyclase inhibition → reduced cAMP in PeVN SST neurons → attenuated PKA-driven somatostatin secretory granule exocytosis from SST neuron axon terminals → lower somatostatin concentration in hypothalamo-pituitary portal blood. Portal SST is the primary physiological brake on somatotroph GH secretion: SST binds SST-R2 (Gαi-coupled somatostatin receptor 2) on somatotrophs → Gαi → adenylyl cyclase suppression → reduced somatotroph cAMP — directly counteracting the GHRH-R/Gs/cAMP signal CJC-1295 generates in parallel. Ipamorelin’s reduction of portal SST thus lifts this Gαi-mediated cAMP-suppressing brake at the same moment CJC-1295 is activating the Gs/cAMP accelerator on the same somatotroph — a press-the-accelerator-while-releasing-the-brake mechanism that produces genuinely supraadditive GH output rather than merely additive effects. This SST-suppression arm operates in parallel with, and independently of, the somatotroph-level IP₃/Ca²⁺/PKC signaling described in the synergy mechanism below — and the combination produces synergistic GH release exceeding either alone. The mechanistic basis for this synergy operates at the level of pituitary somatotroph signal convergence. CJC-1295 engages GHRH-R, a Gs-coupled receptor on somatotrophs → adenylyl cyclase activation → intracellular cAMP rise → PKA activation → two parallel outputs: (a) PKA phosphorylates L-type voltage-gated Ca²⁺ channels in the somatotroph plasma membrane → Ca²⁺ influx → GH secretory granule fusion with the plasma membrane; and (b) PKA phosphorylates CREB (cAMP response element-binding protein) → transcriptional upregulation of GH gene expression → sustained replenishment of the secretory granule pool for subsequent pulses. Ipamorelin, acting at GHSR-1a (a Gαq-coupled receptor on the same somatotrophs), activates PLCβ → IP₃ → IP₃R-mediated ER Ca²⁺ release + DAG → PKC → a second, independent Ca²⁺ transient in the somatotroph cytoplasm. The synergy arises because cAMP/PKA (CJC-1295 arm) and IP₃/Ca²⁺/PKC (ipamorelin arm) are parallel upstream pathways that both converge on the Ca²⁺-dependent GH secretory granule exocytosis machinery. When both receptors are simultaneously activated, cytoplasmic Ca²⁺ transients are larger in amplitude and longer in duration than either signal alone can produce — the combined Ca²⁺ signal recruits more vesicles to the active zone and accelerates SNARE complex assembly between granule VAMP and plasma membrane syntaxin/SNAP-25, producing a supraadditive (multiplicative rather than additive) GH pulse. This dual-pathway convergence model explains why clinical protocols pairing a GHRH analogue with a GHRP consistently produce greater GH output than either class administered alone (Khorram et al., 1997, PMID: 9062479). Clinical marketing can discuss these mechanisms accurately. Specific outcome claims require substantiation.

PT-141 (Bremelanotide)

PT-141 is a melanocortin receptor agonist derived from Melanotan II. Vyleesi (bremelanotide) received FDA approval in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, which provides an approved drug reference point for compounding discussions.

Unlike PDE5 inhibitors (sildenafil, tadalafil) that act peripherally on vascular smooth muscle, PT-141 acts centrally in the hypothalamus — specifically through MC4R (melanocortin-4 receptor) in the medial preoptic area (MPOA), a hypothalamic nucleus that serves as the central integrator of sexual motivation. MC4R is Gs-coupled; PT-141/MC4R → Gαs → adenylyl cyclase → elevated cAMP → PKA activation in MPOA neurons. PKA increases MPOA neuron excitability by shifting HCN (hyperpolarization-activated cyclic nucleotide-gated) channel voltage dependence to more positive membrane potentials → enhanced diastolic depolarizing I_f current → increased baseline MPOA neuron firing rate. Activated MPOA neurons send two parallel projections that together constitute the “desire circuit”:

First, mesolimbic motivation: MPOA projects to the ventral tegmental area (VTA) and suppresses local GABAergic interneurons → dopaminergic VTA neurons projecting to the nucleus accumbens (NAc) shell are disinhibited → increased phasic dopamine release in the NAc → motivational salience encoding for sexual stimuli (the “wanting” component of desire). Second, physiological arousal via oxytocin: MPOA projects to the paraventricular nucleus (PVN) → PVN oxytocin neurons are recruited → oxytocin released from the posterior pituitary → genital sensory sensitization and vasocongestion (lubrication and engorgement in women; contributes to tumescence in men through a distinct NO/cGMP arm at genital vasculature downstream of central arousal).

This central activation upstream of genital vasodilation explains why PT-141 can restore sexual response in patients who do not respond to PDE5 inhibitors: sildenafil/tadalafil act only at the final peripheral cGMP step in vascular smooth muscle, and cannot compensate for absent central desire signaling; PT-141 addresses the upstream motivational and arousal deficit. This central mechanism is also why it has been explored for male sexual dysfunction resistant to PDE5 inhibitors.

Legal status: Category 1, eligible for 503A compounding.

Marketing implications: The approved drug analog (Vyleesi) creates both opportunity and constraint. Marketing cannot imply that the compounded version is equivalent to or interchangeable with the FDA-approved product. Marketing focused on access, cost, or route-of-administration flexibility relative to the branded drug should be carefully reviewed by legal counsel. Nausea — the primary adverse effect affecting roughly 40% of subjects in RECONNECT trials — should be disclosed in patient-facing materials. The mechanism is central rather than peripheral: MC4R is expressed not only in the MPOA/VTA/PVN circuits mediating desire and arousal but also on neurons in the dorsal motor nucleus of the vagus (DMV) and the nucleus tractus solitarius (NTS) in the brainstem. PT-141 binding at brainstem MC4R → Gs/cAMP/PKA → increased vagal efferent outflow to the stomach → gastric fundus relaxation and antral hypomotility → delayed gastric emptying → nausea from gastric distension and altered mechanoreceptor signaling. A second arm operates through the area postrema — the chemoreceptor trigger zone located on the floor of the fourth ventricle, which lacks a blood-brain barrier and is therefore directly accessible to circulating PT-141. Area postrema MC4R activation → local 5-HT release → 5-HT3 receptor-mediated activation of adjacent NTS neurons → dorsal vagal complex integration → nausea signal generation. Together, these two brainstem arms explain the 30–60 minute onset (matching peak plasma concentration) and the dose-dependence of nausea, and they explain why 5-HT3 antagonists (ondansetron) and D2 antagonists (prochlorperazine) — agents targeting brainstem emetic circuitry — are the clinically effective management strategy, rather than prokinetics targeting peripheral gastric motility alone.

Tesamorelin: The Reference Listed Drug (RLD) Complication

Tesamorelin deserves special treatment because its regulatory situation is more complex than other Category 1 compounds. Egrifta (tesamorelin 1 mg) and Egrifta SV (2 mg) are FDA-approved drugs for HIV-associated lipodystrophy. Under FDCA Section 503A(b)(1)(D), a compounding pharmacy cannot compound a drug that is “essentially a copy” of an FDA-approved product (Reference Listed Drug or RLD) unless the prescriber documents that the compounded version is medically necessary for that patient.

This means tesamorelin is theoretically available through 503A but practically constrained: compounding pharmacies must have prescriber documentation of medical necessity for each patient, and the compound must differ from the RLD in a clinically meaningful way — different dose, different formulation, different route. For 503B outsourcing facilities, different rules apply.

In practice, because tesamorelin compounding under 503A requires documented medical necessity and the RLD exists, many practitioners accessing tesamorelin for off-label uses (anti-aging, body composition in non-HIV patients) route through 503B-compliant outsourcing facilities instead.

Why the statutory mechanisms differ between 503A and 503B for tesamorelin: The divergence between these two pathways has a precise basis in FDCA text that practitioners and marketers need to understand. Under FDCA Section 503A(b)(1)(D), the “essentially a copy” prohibition applies unless the prescriber documents patient-specific medical necessity. The FDA’s interpretive guidance is specific: this documentation must contain individualized clinical rationale — a confirmed allergy to an excipient present in Egrifta/Egrifta SV (such as mannitol or benzyl alcohol), a required concentration not commercially available, or a medically necessary route of administration not offered by the approved product. Boilerplate “medical necessity” language is insufficient; the guidance requires the prescriber to identify the specific clinical inadequacy of the commercial product for that patient. This per-prescription attestation burden is logistically prohibitive at scale — every new tesamorelin prescription from a 503A pharmacy requires a fresh patient-specific statement, which makes high-volume off-label prescribing impractical.

Under FDCA Section 503B, outsourcing facilities do not dispense individual prescriptions — they supply healthcare facilities and licensed practitioners. Accordingly, the 503B prohibition on “essentially a copy” (FDCA Section 503B(a)(3)) operates at a population-level clinical need standard: an outsourcing facility can compound a commercially available drug when documentation establishes a clinical gap across the patient population it serves — a concentration not commercially offered, or a formulation excluding an excipient that a defined patient cohort cannot tolerate — without requiring patient-by-patient prescriber attestations. This population-level determination eliminates the documentation bottleneck. The cost of this flexibility is the higher 503B registration burden: FDA facility registration, Current Good Manufacturing Practice (cGMP) compliance, biannual FDA inspections, and lot-release testing requirements that 503A pharmacies do not face. For tesamorelin specifically, the clinical gap argument — that the only commercially available concentrations are 1 mg and 2 mg (HIV-dosing calibrated) while off-label non-HIV protocols may require different concentrations — provides the population-level clinical need documentation that 503B requires, without the individual attestation burden that makes 503A impractical for this use case.

Category 2: Peptides Under Review

Category 2 peptides are nominations the FDA has not completed its review on. During the review period, compounding pharmacies operating in good faith may continue to compound these substances. However, Category 2 status is inherently temporary — FDA’s final decision will place each compound in Category 1 or Category 3.

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid sequence derived from a protein in gastric juice (gastric pentadecapeptide). It has an extensive preclinical research record — wound healing, gut mucosal repair, tendon-to-bone attachment healing, anti-inflammatory effects, and nitric oxide pathway modulation — with multiple mechanisms proposed across different tissue types. The most characterized of these mechanisms is worth understanding because it directly informs the diversity of BPC-157’s reported tissue effects. The VEGFR2/eNOS pathway: BPC-157 transactivates VEGFR2 (vascular endothelial growth factor receptor 2, KDR/Flk-1) on endothelial cells independently of VEGF ligand — the peptide activates the receptor’s intracellular signaling without requiring the normal extracellular VEGF-A binding event through a defined inside-out integrin/Src mechanism: BPC-157’s polyproline/glycine scaffold engages integrin α5β1 (the fibronectin-binding integrin constitutively expressed on endothelial cell surfaces) → integrin cytoplasmic tail conformational change → recruitment and autophosphorylation of c-Src at Tyr418 in its activation loop → activated c-Src (acting as a trans-kinase) directly phosphorylates VEGFR2 at Tyr1175 in the receptor’s kinase domain activation loop — without VEGF occupying the extracellular ligand-binding domain; this single phosphorylation event is sufficient to initiate full VEGFR2 downstream signaling because Tyr1175 is the primary docking site for PLCγ1 and Src-family kinases in the productive VEGFR2 signaling complex. This integrin-Src-VEGFR2 transactivation axis parallels the mechanism by which GPCRs transactivate EGF receptors (EGFR Tyr1068 phosphorylation by Src following GPCR-driven Src activation) and explains why BPC-157 endothelial effects are concentration-dependent on BPC-157 but ligand-independent of exogenous VEGF-A. VEGFR2 Tyr1175 phosphorylation → c-Src tyrosine kinase further amplified → c-Src phosphorylates FAK (focal adhesion kinase) at Tyr397 → FAK activates Erk1/2 (MAPK) → Erk1/2 drives cell cycle entry and migration in endothelial cells and fibroblasts → angiogenesis (endothelial tube formation and capillary sprouting) and fibroblast migration into wound beds. Simultaneously, VEGFR2 activation → eNOS (endothelial nitric oxide synthase) Ser1177 phosphorylation → increased NO production → sGC/cGMP → vasodilation and antiplatelet effects that support wound healing blood flow; cGMP also activates KATP channels in smooth muscle → sustained local vasodilation beyond the eNOS induction window. A complementary arm connects the same ERK1/2 activation (from the c-Src/FAK angiogenesis pathway) to a fibroblast-specific collagen synthesis program through EGR-1: activated ERK1/2 → ERK1/2 phosphorylates Elk-1 (an ETS-domain transcription factor) at Ser383 in its transactivation domain → phospho-Elk-1 associates with SRF (serum response factor) already bound at serum response elements (SREs, consensus 5′-CC(A/T)₆GG-3′) in the proximal EGR1 gene promoter → the phospho-Elk-1/SRF ternary complex recruits Mediator co-activator complex → RNA Pol II engagement → EGR-1 (early growth response protein 1) mRNA transcription. EGR-1 is thus an ERK1/2-downstream transcription factor — its induction is mechanistically downstream of the same VEGFR2/c-Src/FAK/ERK1/2 cascade described above for angiogenesis and fibroblast migration, not a separate, parallel pathway. Once transcribed and translated, EGR-1 protein binds GC-rich response elements (GCE, consensus 5′-GCG(G/T)GGGCG-3′) in the promoters of COL1A1, COL1A2, COL3A1 (collagen I α1/α2 and collagen III), FN1 (fibronectin), and TGFB1 → direct transcriptional upregulation of ECM-building gene programs. Critically, EGR-1’s induction of TGFB1 creates an autocrine amplification loop: TGF-β1 secreted by EGR-1-activated fibroblasts binds TGF-βR I/II on the same and neighboring cells → SMAD2/3 phosphorylation → SMAD2/3-SMAD4 nuclear complex → SMAD-binding elements (SBEs) in the COL1A1/COL1A2 promoters → additional collagen gene induction independent of further BPC-157 stimulation. The cascade therefore propagates beyond the initial BPC-157 concentration pulse, explaining the delayed wound-healing timescale (hours to days) relative to the immediate angiogenic response (minutes). The combination of angiogenesis (vascular supply), fibroblast recruitment and ECM synthesis, and NO-driven microvascular dilation explains why BPC-157 shows effects across diverse tissue types in animal models — it targets the foundational processes of tissue repair rather than a single tissue-specific pathway. The clinical literature in humans is thin: case reports and small series exist, but no large randomized controlled trials.

The regulatory concern: The FDA’s Category 2 designation does not reflect a safety concern so much as an evidence gap. The 503A framework requires that substances have clinical need and safety/efficacy support. With BPC-157, the clinical need argument is plausible (tissue repair, gut conditions without good alternatives), but the absence of human RCT data creates the evidentiary gap that leaves the nomination unresolved. A Category 3 determination would not necessarily mean BPC-157 is dangerous — it might mean the evidence base is insufficient to meet the statutory standard.

Legal status: Category 2. Compounding pharmacies may currently compound it while the review is ongoing.

Marketing implications: This is the most commercially significant regulatory question in the peptide market in 2026. Providers and pharmacies marketing BPC-157 protocols need to:

1. Communicate that the compound is legally compoundable under current FDA policy while review is ongoing — not that it has been approved
2. Avoid implying it has the same approval basis as Category 1 compounds
3. Monitor FDA guidance closely — a Category 3 determination would immediately end compounding eligibility and require rapid wind-down
4. Focus marketing on the research basis and clinical protocols, not on regulatory permanence

Brands that communicate clearly and accurately about where BPC-157 actually stands — rather than overclaiming stability — build trust with the sophisticated buyers who drive the most value in this market.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic version of a bioactive fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide involved in actin dynamics, cell migration, angiogenesis, and anti-inflammatory signaling. Endogenous Tβ4 is expressed in virtually all human cells and is highly concentrated in platelets (approximately 0.5 mM intracellular, far exceeding the ~10 nM serum background), where it is released during platelet activation through a non-classical secretion mechanism distinct from dense- and α-granule exocytosis. Unlike platelet dense granules (ADP, serotonin) and α-granules (fibronectin, VWF, thrombospondin-1) that release contents via Ca²⁺-triggered SNARE-mediated membrane fusion, Tβ4 is a free cytoplasmic protein — not packaged into storage granules — and exits via two parallel mechanisms. First, thrombin/PAR-1 or collagen/GPVI receptor activation → Gq/PLCβ → IP₃/DAG → intracellular Ca²⁺ rise → activation of PLSCR1 (phospholipid scramblase 1) → phosphatidylserine flips from the inner to outer plasma membrane leaflet → membrane curvature instability → the activated platelet’s membrane undergoes blebbing and microparticle budding (driven by Ca²⁺-dependent cytoskeletal actomyosin contraction that pushes membrane outward while cytoplasmic pressure drives inward) → platelet-derived microparticles (PDMPs) incorporating cytoplasmic contents including Tβ4 are shed into the wound environment. Second, platelet shape change — thrombin-driven disc-to-sphere transition then pseudopod extension and lamellipodia spreading — involves cytoskeletal reorganization that transiently disrupts the cortical actin shell; cytoplasmic Tβ4, normally bound to G-actin within the stable platelet cytoskeleton, is released into the pericellular space as cytoskeletal remodeling displaces the sequestered G-actin pool. Both mechanisms converge to generate wound-fluid Tβ4 concentrations 10–100 times higher than serum.

The “actin dynamics” mechanism is worth unpacking, because it explains both the breadth of Tβ4’s proposed tissue effects and why the clinical translation is still incomplete. Tβ4 is the most abundant intracellular G-actin sequestering peptide in vertebrate cells. Its central activity is binding G-actin (globular, monomeric actin) via a conserved LKKTET motif, holding actin in the monomer pool and preventing spontaneous F-actin (filamentous actin) polymerization under basal conditions. When a cell receives a prohealing or migratory signal, factors like cofilin (which severs existing F-actin, generating new free barbed ends) and the Arp2/3 complex (which nucleates branched actin filaments at the leading edge of lamellipodia) compete for G-actin monomers that Tβ4 had sequestered. Release of sequestered G-actin allows rapid F-actin network remodeling that drives cell polarization and directional migration — the cellular behavior required for fibroblasts to migrate into a wound bed and for endothelial cells to extend into new vascular sprouts. Tβ4 also has a documented nuclear role: it can translocate to the nucleus and interact with PINCH (Particularly Interesting New Cysteine-His protein), activating ILK (integrin-linked kinase) signaling, which promotes cell survival via Akt and regulates epithelial-to-mesenchymal transition — a process relevant to both fibrosis repair and tissue remodeling. The ILK survival mechanism is mediated by the IPP (ILK/PINCH/Parvin) ternary complex: PINCH1 (encoded by LIMS1) is a LIM-domain scaffold protein that binds ILK’s N-terminal ankyrin repeat domain; alpha-parvin simultaneously binds ILK’s C-terminal pseudokinase domain; together with Tβ4’s nuclear stabilization of the PINCH1 interaction, this IPP complex anchors ILK to integrin β-subunit cytoplasmic tails at focal adhesions. The assembled ILK within the IPP complex acts as a scaffold for recruiting both PDK1 (which phosphorylates Akt at Thr308 in the activation loop via the kinase activation segment mechanism) and mTORC2 (which phosphorylates Akt at Ser473 via the mLST8/Rictor-dependent active site). Akt doubly phosphorylated at Thr308 and Ser473 is maximally active (full active-site and substrate-binding groove engagement) and drives two parallel survival outputs: (1) BAD Ser136 phosphorylation → BAD (BCL-2 antagonist of cell death) is phosphorylated by Akt at Ser136 → phospho-BAD is recognized by 14-3-3σ proteins (dimeric phosphoserine-binding adaptors) → 14-3-3σ sequesters phospho-BAD in the cytoplasm → BAD can no longer translocate to the mitochondrial outer membrane to heterodimerize with Bcl-2 or Bcl-xL → Bcl-2/Bcl-xL remain free to occupy and block Bax/Bak oligomerization pores → the outer mitochondrial membrane remains intact → cytochrome c is not released into the cytoplasm → the apoptosome (Apaf-1/cytochrome c/procaspase-9) cannot assemble → executioner caspase-3 is not activated → cell death is prevented. (2) GSK-3β Ser9 phosphorylation → active Akt phosphorylates GSK-3β (glycogen synthase kinase 3β) at the N-terminal inhibitory Ser9 → the phosphorylated Ser9 pseudo-substrate domain folds back and occupies the positively-charged substrate-binding site, acting as an autoinhibitory clamp → GSK-3β cannot phosphorylate its downstream substrates. In the EMT context this is most consequential for β-catenin: unphosphorylated β-catenin escapes the destruction complex (which requires GSK-3β Ser33/Ser37/Thr41 phosphorylation on β-catenin → β-TrCP ubiquitin ligase recognition → proteasomal degradation) → cytoplasmic β-catenin accumulates → nuclear translocation → β-catenin/TCF4 transcriptional complex → target genes including vimentin, N-cadherin, fibronectin, and Snail, which collectively drive mesenchymal phenotype acquisition required for fibroblast activation and tissue remodeling. This is why Tβ4’s pleiotropy — cytoskeletal G-actin sequestration driving migration, plus ILK/IPP/Akt/BAD survival signaling, plus β-catenin/TCF4 EMT transcription — operates simultaneously across the wound repair program rather than as separable independent effects: all three arms are activated together when the IPP complex assembles in response to integrin engagement at the wound edge. The pleiotropy of Tβ4 biology (cytoskeletal remodeling, angiogenesis, survival signaling) explains why preclinical models show effects across diverse tissue types; it also explains why mechanistic characterization has outpaced the clean, indication-specific human trial data the FDA’s 503A framework requires.

Legal status: Category 2. Under FDA review, currently compoundable.

Marketing implications: Similar to BPC-157 — communicate the current compoundable status accurately, avoid implying permanence, monitor for FDA guidance updates. The research literature on TB-500 is less extensive than BPC-157 in tissue repair models, which constrains some marketing angles but does not change the compliance framework.

GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) with proposed roles in wound healing, collagen synthesis, and anti-inflammatory signaling — each with a partially characterized molecular mechanism. For collagen synthesis: GHK-Cu serves as a physiological Cu²⁺ chaperone that delivers copper ions to lysyl oxidase (LOX), a copper-dependent amine oxidase secreted by fibroblasts into the extracellular matrix. LOX oxidizes the ε-amino groups of specific lysine and hydroxylysine residues in newly deposited collagen chains → aldehyde intermediates → spontaneous formation of allysine-derived covalent crosslinks between adjacent tropocollagen molecules → mechanically stable, mature collagen fibrils. GHK tripeptide activates TGF-β1 production in dermal fibroblasts through a two-arm mechanism. In the transcriptional arm: GHK’s His-Lys dipeptide scaffold engages integrin α2β1 (the collagen-recognition integrin constitutively expressed on dermal fibroblasts, whose I-domain binds collagen’s Gly-Pro-Hyp motif; the GHK tripeptide mimics a related collagen-sequence fragment at this site) → integrin clustering → FAK Tyr397 autophosphorylation → FAK recruits PI3K regulatory subunit p85α via SH2 domain/Tyr397 interaction → PI3K catalytic p110α generates PIP3 at the inner plasma membrane leaflet → Akt Thr308 (PDK1-mediated) and Ser473 (mTORC2-mediated) phosphorylation → doubly phosphorylated Akt phosphorylates Sp1 (specificity protein 1) at Thr453 and Thr739 in Sp1’s C-terminal regulatory domain → phospho-Sp1 increases affinity for GC-box elements (5′-GGGCGGGC-3′) in the TGFB1 proximal promoter → TGF-β1 mRNA and secreted precursor. In the latent-release arm: the Cu²⁺ delivered by GHK-Cu activates extracellular LOX → increased fibronectin/collagen ECM crosslinking → elevated matrix stiffness → integrin αvβ3/αvβ5 mechanosensing on fibroblast lamellipodia → RhoA/ROCK → actomyosin contractility → tensile traction forces transmitted through fibronectin to the LTBP1-anchored latent TGF-β1 large complex (LLC: LTBP1 + proTGF-β1 + LAP) crosslinked into the ECM → tensile force on LTBP1 induces conformational change in LAP (latency-associated peptide), dissociating the prodomain clamp from the TGF-β1 dimer → mechanically released bioactive TGF-β1 binds TGFβRII/ALK5 on neighboring fibroblasts → SMAD2/3 phosphorylation → nuclear translocation → SMAD-responsive elements in the COL1A1 and COL1A2 promoters → increased type I procollagen gene transcription. The dual Sp1-transcriptional and LAP-mechanical release arms explain the autocrine TGF-β1 amplification loop that sustains collagen synthesis beyond the initial GHK-Cu exposure window — and why GHK-Cu’s collagen effects operate at concentrations below those needed to fully saturate the Keap1/Cys151 anti-inflammatory arm described below. For anti-inflammatory effects: free Cu²⁺ ions are pro-oxidant — they catalyze Fenton-like reactions (Cu⁺ + H₂O₂ → OH• + OH⁻) that drive lipid peroxidation and protein carbonylation; GHK chelates free Cu²⁺ in a stable square-planar complex (coordinated via the Gly α-amino group, His imidazole N1, and Lys α-amino group) → reduced free Cu²⁺ available for ROS generation → lower oxidative stress in peri-wound tissue; additionally, GHK-Cu suppresses NF-κB nuclear translocation in activated macrophages via the Keap1/NRF2/HO-1/IKKβ axis: the Cu²⁺ ion from the GHK-Cu complex alkylates sensor cysteine residues on Keap1 (specifically Cys151, Cys273, and Cys288) → disrupts Keap1’s ability to assemble a functional Cullin-3/RBX1 E3 ubiquitin ligase complex targeting NRF2 → NRF2 escapes proteasomal degradation and accumulates in the nucleus → NRF2/sMaf heterodimer binds antioxidant response elements (ARE) in the HO-1 (heme oxygenase-1) gene promoter → HO-1 protein is induced; HO-1 catabolizes intracellular heme → CO + biliverdin + Fe²⁺; CO activates soluble guanylate cyclase (sGC) → cGMP elevation → PKG (protein kinase G) → PKG phosphorylates IKKβ at an inhibitory serine residue (Ser180) → IKKβ cannot phosphorylate IκBα at Ser32/Ser36 → IκBα retains the p65/p50 NF-κB dimer in the cytoplasm → reduced NF-κB nuclear translocation → reduced transcription of TNF-α, IL-1β, and IL-6 (PMID:24955487; PMID:29988121). It occurs endogenously in human plasma and tissue, and concentrations decline with age — a pattern that has generated interest in aesthetic medicine and systemic anti-aging protocols.

Legal status: Category 2. Under FDA review.

Marketing implications: GHK-Cu’s dual product landscape — injectable compounded preparations operating under Category 2 parenteral compounding rules, and topical formulations sold commercially in aesthetic medicine — creates a regulatory bifurcation that marketers must understand precisely, because the same molecule in two delivery formats carries entirely different regulatory obligations determined by the claims attached to it.

Injectable compounded GHK-Cu is subject to the 503A/503B framework governing parenteral compounding. Category 2 status means it is currently compoundable under FDA review, with the compliance obligations described above for all Category 2 compounds: accurate communication of review status, no equivalence claims against approved products, active monitoring of PCAC proceedings.

Topical GHK-Cu formulations operate under the cosmetic/drug boundary — a regulatory line drawn not by delivery format but by the intended use communicated through labeling, advertising, and any associated claims. The applicable statute is the Federal Food, Drug, and Cosmetic Act’s two adjacent definitions: Section 201(i) defines cosmetics as articles “intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body… for cleansing, beautifying, promoting attractiveness, or altering appearance” — with no reference to affecting structure or function. Section 201(g)(1)(C) defines a drug as any article “(other than food) intended to affect the structure or any function of the body” — a definition that extends to topical products when their labeling or advertising asserts a physiological effect on skin. Intended use is determined from the totality of evidence the FDA can collect: label text, website copy, testimonials, social media posts, and any oral or written statements by the company or its representatives — not just the principal display panel.

The specific claims that cross the line. A topical GHK-Cu product marketed as “hydrating and smoothing the skin surface” is making appearance claims (cosmetic). The same product promoted as “stimulating collagen synthesis,” “increasing dermal collagen density,” “activating fibroblast proliferation,” or “improving skin architecture” is making structure or function claims — the skin’s collagen matrix and cellular activity are structural and functional elements, and claiming to modify their quantity or behavior constitutes a drug claim under Section 201(g)(1)(C). The FDA’s own guidance on cosmetic/drug boundaries identifies collagen synthesis claims specifically as drug-defining language. The regulatory consequence is immediate: a product with a drug claim but no NDA or ANDA approval is an unapproved new drug subject to FDCA Section 301(a) enforcement (introduction of misbranded or unapproved drugs into interstate commerce). The FDA’s authority is post-market, but warning letters, injunctions, product seizure, and criminal prosecution for knowing violations are all available remedies applied in this context.

The “cosmeceutical” trap. The term “cosmeceutical” is widely used in aesthetic medicine to imply both cosmetic elegance and drug-like efficacy. It is not a regulatory category and provides no legal protection. A product marketed as a cosmeceutical is legally either a cosmetic (if claims remain within appearance territory) or an unapproved drug (if they reference structural or functional effects on skin). The term’s implicit promise of drug-level biological activity is precisely what makes it a regulatory liability when the FDA scrutinizes accompanying marketing.

Practical compliance guidance. Marketing language anchored to appearance descriptors — “helps maintain a smooth, even skin appearance,” “supports skin’s natural moisture barrier,” “promotes a radiant look” — remains within cosmetic territory. Language referencing biological mechanisms — “activates collagen-synthesis pathways,” “increases dermal matrix density,” “stimulates cellular renewal” — crosses into drug claim territory. For GHK-Cu specifically, the copper-LOX collagen crosslinking and TGF-β1/SMAD2/3 signaling mechanisms that make it scientifically interesting are the exact same mechanisms that, if referenced in product marketing, constitute drug claims. The more mechanistically accurate the marketing, the more likely it requires drug-approval infrastructure the brand does not hold.

AOD-9604

AOD-9604 is the C-terminal fragment of human growth hormone spanning residues 177–191 — a 15-amino acid sequence also designated “hGH frag 177-191.” Its development rationale rests on a mechanistic question: whether the lipolytic activity of full-length GH can be structurally separated from its growth-promoting activity, eliminating the diabetogenic and IGF-1-elevating effects that constrain full GH use in obesity treatment.

Full GH’s lipolytic mechanism — and why it creates problems. Full-length GH binds GHR (the GH receptor), inducing receptor dimerization and JAK2 transphosphorylation → JAK2 phosphorylates STAT5b Tyr699 → pSTAT5b dimerizes and translocates to the nucleus → binds GAS elements in the hepatic IGF1 gene promoter → IGF-1 synthesis and secretion. This is the growth-promoting arm responsible for GH’s anabolic effects on bone and muscle — and the IGF-1 induction is also responsible for insulin resistance at supraphysiological GH doses (hepatic IGF-1 activates IRS-1/PI3K pathways that paradoxically compete with insulin’s own IRS-1 signaling, creating selective insulin resistance). Separately, GH drives adipocyte lipolysis through a distinct intracellular arm: GHR → JAK2 → IRS-1 phosphorylation in adipocytes → PI3K → mTORC2 → Akt Ser473; and via a parallel route GHR → Gαs → adenylyl cyclase → cAMP → PKA → PKA phosphorylates HSL (hormone-sensitive lipase) at Ser563, Ser659, and Ser660 → activated HSL hydrolyzes stored triglycerides → diglyceride + free fatty acid released → systemic fat mobilization. The problem with using full GH as an obesity treatment at lipolytic doses is that the same JAK2/STAT5b/IGF-1 axis that drives growth-promotion is inseparable from the lipolytic signaling when full GH is used — both effects occur together. The specific mechanism explaining this inseparability operates at the IRS-1 convergence point. Full GH activates JAK2 in skeletal muscle → JAK2 recruits and activates the mTOR/S6K1 arm (via a parallel PI3K/mTORC1 pathway distinct from the adipocyte lipolysis mTORC2/Akt-Ser473 arm described above) → S6K1 phosphorylates IRS-1 at Ser307 (and Ser636) → these inhibitory serine phosphorylations induce an IRS-1 conformational change that blocks the insulin receptor tyrosine kinase domain from phosphorylating IRS-1’s activating tyrosine residues (Tyr612/Tyr632) → PI3K cannot be recruited to the phosphotyrosine docking motif → Akt/GLUT4 pathway is impaired → peripheral insulin resistance. Simultaneously, GH-driven HSL activation in adipocytes (the lipolytic arm, via the PKA/HSL pathway described above) releases free fatty acids into circulation → FFAs enter skeletal muscle myocytes → incomplete β-oxidation generates diacylglycerol (DAG) and ceramide → DAG activates PKCθ (protein kinase C theta, the isoform predominant in skeletal muscle) → PKCθ phosphorylates IRS-1 Ser307 through the same inhibitory site as the JAK2/S6K1 arm. The adipocyte-derived FFA lipolysis signal (GH → HSL → FFA → DAG/ceramide → PKCθ → IRS-1 Ser307) and the direct muscle kinase signal (GH → JAK2 → mTOR/S6K1 → IRS-1 Ser307) converge redundantly on the same serine phosphorylation target, meaning the two cannot be dissociated at the GHR level: any dose of full GH sufficient to activate HSL for lipolysis simultaneously activates S6K1 and generates the downstream FFA burden that activates PKCθ, making insulin resistance a structural consequence of the lipolytic mechanism rather than a separable side effect. This convergence at IRS-1 Ser307 is the mechanistic basis for why AOD-9604’s β3-AR/PKA/HSL pathway — which bypasses GHR and therefore bypasses JAK2/S6K1 activation — does not recapitulate the insulin resistance seen with full GH even at equivalent lipolytic effect, and why the Phase I/II measurements confirming normal fasting glucose and insulin sensitivity with AOD-9604 represent a genuinely meaningful safety differentiation from full GH therapy.

AOD-9604’s mechanistic distinction. The 177–191 C-terminal fragment lacks the portion of the GH molecule required to engage GHR’s binding site I and site II in a configuration that drives productive JAK2 transphosphorylation and STAT5b nuclear translocation. As a result, AOD-9604 does not generate the JAK2/STAT5b cascade, does not induce hepatic IGF-1 synthesis, and does not cause insulin resistance — confirmed in Phase I and early Phase II human trials that measured circulating IGF-1 and glucose/insulin homeostasis at multiple doses. The fragment appears to interact with adipocyte surface receptors — evidence points toward β3-adrenergic receptor (ADRB3) as a candidate, with the C-terminal GH helix competent to engage the β3-AR’s hydrophobic binding pocket — triggering Gs → adenylyl cyclase → cAMP → PKA → HSL phosphorylation in white adipocytes: the same PKA/HSL lipolytic arm as full GH, but accessed without routing through GHR/JAK2. This receptor characterization remains incompletely validated — the literature does not yet reach consensus on the precise receptor responsible, and some researchers propose an uncharacterized fragment-selective receptor.

The clinical translation gap. Phase IIa trials in overweight and obese patients reported modest body-weight reductions versus placebo. Phase IIb trials at multiple dose levels (0.25mg to 9mg) failed to demonstrate statistically significant weight loss separating from placebo. The mechanistic selectivity concept was validated (no IGF-1 elevation, no diabetogenic effect), but converting selective adipocyte lipolysis into clinically meaningful weight loss proved more difficult than the preclinical models suggested — and the mechanism of failure is instructive. When adipocyte ATGL/HSL activation releases free fatty acids into systemic circulation, rising plasma FFAs are sensed by the hypothalamus: FFAs cross the blood-brain barrier via FATP1/CD36 transporters → intraneuronal FFA-CoA accumulates in AgRP/NPY neurons of the arcuate nucleus → local malonyl-CoA levels decline (reduced ACC substrate flux in the catabolic neuron context) → CPT1A disinhibited → increased intraneuronal FA oxidation → AMPK activation (through reduced ATP production from mitochondria stressed by substrate surplus) → AMPK-mediated signaling reduces Akt activity → FoxO1 is not phosphorylated out of the nucleus → FoxO1 binds FHRE (Forkhead Response Elements) in the AgRP and NPY gene promoters → increased AgRP and NPY mRNA and peptide secretion. AgRP acts as an inverse agonist at MC4R in the paraventricular nucleus → suppresses the anorectic POMC/α-MSH circuit → drives food intake increase. This compensatory hyperphagia refills the caloric deficit created by fat mobilization, explaining the Phase IIb null result: the lipolytic mechanism was real, but the brain interpreted rising plasma FFAs as a signal to eat more, neutralizing the effect. GLP-1 agonists escape this counter-regulation by simultaneously activating central POMC/MC4R appetite suppression alongside metabolic effects — the appetite-suppressive component outpaces the compensatory orexigenic response. AOD-9604, acting only on the downstream lipolytic output, has no equivalent upstream brake on hyperphagia. The compound is currently under Category 2 review at the FDA.

Legal status: Category 2. Under FDA review.

Marketing implications: AOD-9604’s principal marketing asset is its mechanistic selectivity — the data demonstrating that it does not elevate IGF-1 or cause insulin resistance is real and accurately communicable. The clinical efficacy data does not support weight-loss outcome claims. Marketing should focus on mechanism, research context, and the ongoing regulatory review status without overclaiming based on preclinical or Phase IIa data that did not translate through Phase IIb.

What the selectivity data actually proves — and why Phase IIb failure does not undermine it. The IGF-1 non-elevation finding is among the most clinically meaningful data points a GH-axis peptide can produce. Full GH administration raises circulating IGF-1 substantially; elevated IGF-1 drives mitogenic signaling through IGF-1R/PI3K/Akt/mTOR in epithelial tissues and is a recognized concern in contexts of cancer surveillance, post-treatment oncology follow-up, and patients with family histories of IGF-1-sensitive malignancies. AOD-9604’s C-terminal hGH fragment (Tyr444–Phe191 in the mature sequence) lacks the N-terminal domain required for productive GHR dimerization in hepatocytes and myocytes — the receptor conformation that initiates JAK2/STAT5b → IGF-1 transcription in liver; instead, AOD-9604 engages β3-adrenoceptor on adipocytes directly and activates HSL through Gs/adenylyl cyclase/cAMP/PKA without touching the GHR/JAK2/STAT5b hepatic axis. This selectivity is not a theoretical claim — it was directly confirmed in Phase I/II human trials measuring fasting IGF-1 and insulin levels across dose ranges. Those measurements stand independently of the Phase IIb outcome. The Phase IIb null result reflects a specific failure mode: the AgRP/FoxO1/NPY compensatory hyperphagia mechanism neutralized the caloric deficit created by HSL-driven lipolysis, a counter-regulatory circuit that GLP-1 agonists bypass through simultaneous central appetite suppression. The selectivity mechanism — β3-AR/PKA/HSL specificity with GHR bypass — was not falsified by Phase IIb; the hyperphagia mechanism simply dominated the net energy balance outcome. These are separable claims. Marketing can accurately state that AOD-9604 has human clinical data confirming absence of IGF-1 elevation and no insulin resistance induction at studied doses; that this safety-differentiation profile addresses a real concern for GH-axis therapies; and that ongoing FDA Category 2 review reflects regulatory engagement with the compound’s distinct mechanism. What cannot be claimed is weight-loss efficacy based on Phase IIb failure and Phase IIa data that did not replicate at scale.

The GLP-1 Compounding Case Study: How Fast Status Can Change

The semaglutide and tirzepatide compounding controversy of 2024–2025 is the most important recent case study in how rapidly FDA enforcement can shift the compounding market — and what it means to market a compound without attending to regulatory fundamentals.

The Shortage Exception and Its Limits

During 2022–2024, the FDA placed semaglutide and tirzepatide on the drug shortage list. Under FDCA Section 503A and 503B, pharmacies may compound copies of drugs that appear on the FDA’s shortage list — even drugs not otherwise eligible for compounding. This created a legal window for mass compounding of GLP-1 receptor agonists.

Compounding pharmacies ramped up rapidly. Telehealth platforms built entire business models around compounded semaglutide. At peak, hundreds of 503A pharmacies and 503B outsourcing facilities were producing semaglutide formulations, often at significantly lower cost than branded Ozempic or Wegovy.

The Enforcement Response

When the FDA removed semaglutide from the shortage list in early 2025, the legal window for shortage-based compounding closed — in stages. The regulatory cascade that produced enforcement is specific and instructive. Under FDCA Section 503A(b)(1)(D) and 503B(a)(3), a compounding pharmacy cannot produce a preparation that is “essentially a copy” of a commercially available, FDA-approved drug. The shortage exception had suspended this prohibition while semaglutide and tirzepatide appeared on the shortage list — because the approved products were genuinely unavailable in sufficient quantities. The moment the FDA removed these drugs from the shortage list (based on manufacturer attestations of adequate supply), the shortage exception evaporated automatically. What had been legally permissible compounding the day before the removal became an “essentially a copy” violation the day after — no new regulatory rulemaking required, because the prohibition had always been there, temporarily suspended. The statutory hook for enforcement: FDCA Section 301(a) prohibits the introduction of adulterated or misbranded drugs into interstate commerce, and a compounded drug that is essentially a copy of an available approved product is legally considered misbranded under Section 502 (it makes claims only an approved drug can make) and potentially unapproved under Section 505. This is the mechanism by which shortage-list removal instantly transformed hundreds of 503A and 503B operations from legal compounders into potential enforcement targets without any change to the underlying statute.

The FDA issued guidance giving 503B outsourcing facilities a wind-down period but signaling that continued compounding beyond the deadline would face enforcement. For 503A pharmacies, the timeline was tighter — because 503A pharmacies dispense patient-specific prescriptions (no new prescriptions could lawfully be written for essentially-a-copy semaglutide), while 503B facilities had existing inventory and hospital/healthcare provider supply relationships that required orderly rundown. The distinction reflects the structural difference between the frameworks: 503A compounding is transaction-specific (fill this prescription for this patient), so the exception turns off at the prescriber level; 503B compounding involves bulk production for institutional distribution, requiring a logistical wind-down period to prevent abrupt patient care disruption.

The aftermath involved:

• FTC and state AG investigations into platforms marketing compounded GLP-1s
• FDA warning letters to specific outsourcing facilities for “essentially a copy” violations
• Several telehealth platforms pausing or restructuring their GLP-1 compounding programs
• Litigation from Novo Nordisk and Eli Lilly against platforms they alleged were misleadingly marketing compounded versions

The lesson for the peptide market: Category 2 status is not a permanent operating license. The GLP-1 experience demonstrates that the transition from “legally compoundable” to “enforcement action” can happen in months — specifically because the underlying prohibition (essentially a copy) never disappeared; it was only suspended by the shortage exception. Any compound whose compoundability depends on a temporary FDA status (shortage, Category 1 evaluation, or clinical difference claim) is subject to the same dynamic.

Category 3: Peptides Not Eligible for Compounding

Category 3 designations reflect FDA determinations that a substance should not be included on the 503A Bulks List. Compounding pharmacies cannot lawfully compound these substances for patient use.

Epithalon, Selank, and Semax

These peptides are primarily compounds with limited US clinical use history, often with research originating in Russian and Eastern European scientific institutions. Epithalon (Ala-Glu-Asp-Gly, a tetrapeptide proposed to activate telomerase through a chromatin-remodeling mechanism: preclinical data suggest Epithalon enters somatic cells and induces PCAF/CBP histone acetyltransferase activity at the hTERT promoter, increasing chromatin accessibility and hTERT transcription; elevated hTERT expression assembles the telomerase ribonucleoprotein complex — TERT reverse transcriptase + TERC RNA template — which adds TTAGGG repeats to shortened telomeric 3′ overhangs, reducing per-division telomere attrition and delaying the p53/p21^CIP1-mediated replicative senescence checkpoint that fires when critically short telomeres trigger a persistent DNA damage response [PMID:15916997]; these effects have been observed in human somatic cell cultures and in rodent aging models, though no Phase II/III human trials exist), Selank (a heptapeptide anxiolytic that acts through inhibition of neprilysin/neutral endopeptidase (NEP, CD10) — by blocking NEP-mediated cleavage of Met-enkephalin and Leu-enkephalin at the Gly-Phe peptide bond, selank prolongs endogenous enkephalin dwell-time in limbic synapses → sustained MOR/DOR Gαi coupling → GIRK channel opening → membrane hyperpolarization of amygdala principal neurons and locus coeruleus NE neurons, and Gαi/adenylyl cyclase inhibition → reduced cAMP → attenuated anxiety-circuit excitatory transmission; the FDA Category 3 determination reflects that anxiety as an indication is adequately addressed by approved medications including benzodiazepines and buspirone, and that no US IND-based clinical trial data documents a distinct clinical need or superiority margin), and Semax (a synthetic hexapeptide derived from the ACTH 4-10 sequence — Met-Glu-His-Phe-Arg-Trp-Gly — that promotes BDNF and NGF upregulation in hippocampal and cortical neurons through a two-pronged transcriptional mechanism: the ACTH 4-10 fragment engages MC4R (melanocortin 4 receptor, a Gαs-coupled GPCR expressed on hippocampal pyramidal neurons and cortical projection neurons) → Gαs → adenylyl cyclase → cAMP → PKA → CREB Ser133 phosphorylation → phospho-CREB binds cAMP response elements (CREs, consensus TGACGTCA) in BDNF promoter IV (the activity-dependent promoter most responsive to neuronal cAMP and Ca²⁺ signaling) and in the NGF gene promoter → BDNF and NGF mRNA transcription; PKA simultaneously activates Sp1 co-activator complexes constitutively bound to GC-box elements in BDNF promoter I and promoter II → augmented basal BDNF promoter occupancy and transcriptional output. Released BDNF binds TrkB (NTRK2) → receptor dimerization → transphosphorylation at Tyr490 → Shc/Grb2/SOS → Ras/Raf/MEK/ERK/RSK2/CREB → Arc and c-Fos transcription enabling synaptic remodeling; Tyr490 also recruits PI3K/Akt → mTORC1/4E-BP1/S6K1 → dendritic mRNA translation for structural plasticity. NGF activates TrkA (NTRK1) on cholinergic basal forebrain neurons through the same PI3K/Akt survival axis and Ras/ERK/CREB plasticity cascade; the Category 3 status reflects absence of Phase II/III human data from FDA-recognized IND clinical trials, no approved NDA or IND infrastructure in the US, and insufficient documentation of clinical need distinct from available treatments) are available in some international markets but have not followed the FDA nomination pathway successfully.

The FDA’s Category 3 determinations for these compounds reflect a combination of factors that the Pharmacy Compounding Advisory Committee (PCAC) evaluates through a structured framework, each with a distinct evidentiary mechanism. The “clinical need that cannot be met by approved alternatives” standard operates through a comparative pharmacotherapy analysis: the PCAC reviews whether the proposed therapeutic application of the nominated compound could be served by any currently approved drug, applying a standard that mirrors the FDA’s orphan drug “same indication” analysis under 21 U.S.C. § 360bb. For Selank’s primary indication (anxiety), the PCAC identifies the available approved pharmacotherapy landscape — SSRIs (fluoxetine, sertraline, escitalopram acting via SERT/5-HT reuptake blockade), SNRIs (venlafaxine acting via dual SERT/NET), buspirone (5-HT1A partial agonist/D2 antagonist), and benzodiazepines (GABA-A positive allosteric modulators) — and determines that anxiety as a clinical indication is already “adequately addressed” by approved medications under the Section 503A(b)(1)(C) exception framework. A nominator can rebut this determination only by documenting that Selank’s neprilysin/enkephalin mechanism produces clinically distinct outcomes (e.g., no benzodiazepine-type dependence, no SSRI sexual side effects) in a defined patient population through IND-based US human trial data — and no such IND trial has been completed. For Semax (cognitive enhancement/neuroprotection), no approved drug creates a categorical “adequately addresses” comparison, but PCAC interpretation holds that the absence of an approved comparator does not itself satisfy clinical need — the nomination must present human pharmacokinetic and pharmacodynamic data from FDA-recognized clinical trials establishing that a real therapeutic gap exists in a defined patient population, and no US IND clinical program exists for Semax. The “manufacturing standardization” concern operates through 21 CFR Part 207 drug manufacturer registration and Drug Master File (DMF) requirements: bulk drug substances used in 503A compounding must derive from a facility registered as an Active Pharmaceutical Ingredient (API) manufacturer under 21 CFR Part 207, and the API must be supported by a Type II DMF (drug substance DMF) filed with the FDA that documents manufacturing process, specifications, and analytical methods. Epithalon, Selank, and Semax manufactured in Russian and Eastern European facilities are typically not supported by US FDA facility registrations or DMF filings — the FDA cannot inspect the manufacturing site under its domestic inspection authority, the analytical specifications have not been reviewed against US pharmacopeial standards, and no chain-of-custody documentation linking the raw peptide to GMP-certified synthesis is available in a format the agency can audit. This supply-chain traceability gap constitutes a safety-documentation deficit that is treated as an independent basis for Category 3 status even if the clinical need and clinical data questions were resolved.

The Research Use Only (RUO) Designation

Category 3 compounds may still be sold by chemical suppliers as “Research Use Only” (RUO) materials — a designation that applies to laboratory and in vitro research contexts. RUO products:

• Cannot be marketed for human use
• Cannot be promoted for administration to humans
• Are sold without clinical-grade quality assurance standards (no GMP requirement)
• Are not regulated as drugs

The RUO designation is not a regulatory loophole for compounding pharmacies. A pharmacy that compounds and dispenses an RUO-sourced Category 3 peptide for patient administration is operating outside FDA guidelines and faces significant enforcement risk, regardless of how the ingredient is labeled. The specific statutory violations are layered and difficult to cure through labeling alone. First, adulteration under FDCA Section 501(a)(2)(B): A compounded drug is adulterated if it was not prepared, packed, or held under conditions that conform to cGMP requirements (21 CFR Parts 210 and 211). RUO chemical suppliers are not registered as drug manufacturers under 21 CFR Part 207, have no cGMP certification, and their materials are not classified as Active Pharmaceutical Ingredients (APIs) meeting the identity, purity, and quality standards that cGMP mandates. A compounding pharmacy using RUO-sourced raw material introduces an ingredient that is, by definition, not a cGMP-compliant API — making the finished compounded preparation presumptively adulterated under the statute. Second, the bulk drug substance requirement under FDCA Section 503A(b)(1)(A): 503A permits compounding only from bulk drug substances that are “the subject of a United States Pharmacopeia or National Formulary monograph” or that have a “certificate of analysis from the manufacturer of the active pharmaceutical ingredient” satisfying specific identity and purity criteria. An RUO-grade raw material purchased from a chemical supplier does not carry an API-grade COA acceptable under 503A’s interpretive guidance — the FDA’s position is that the COA must come from a facility registered as a drug manufacturer, not a research reagent supplier. This statutory language makes the ingredient deficiency a 503A non-compliance at the input stage, not merely a quality management concern. Third, enforcement exposure under FDCA Section 301(a): Introducing an adulterated drug into interstate commerce is a prohibited act under Section 301(a). Because most compounding involves materials shipped across state lines (RUO chemicals purchased from out-of-state suppliers, prescriptions filled for out-of-state patients), the interstate commerce element is typically satisfied trivially. The combination of an adulterated designation (from the cGMP failure) and interstate introduction creates Section 301(a) exposure that applies to the pharmacy, potentially the prescribing physician who directed use, and any distributor in the supply chain. “Research Use Only” on the supplier’s label does not transfer to, qualify, or cure the regulatory status of what the pharmacy actually does with the material — the final compounded preparation is evaluated on its own regulatory merits, independent of how the input was labeled by its original supplier.

Compliance warning: Marketing agencies and content teams should not create materials that position Category 3 compounds as available through legitimate US compounding channels. Doing so creates regulatory exposure for the pharmacy, the marketer, and potentially the prescribing provider.

What Happens When Category 2 Becomes Category 3

If the FDA issues a final rule moving a Category 2 compound to Category 3, the practical timeline for pharmacies and marketers is:

Immediate effect (day of Federal Register publication):

• New prescriptions for the compound cannot be filled at 503A pharmacies
• New batches cannot be initiated at 503B outsourcing facilities
• Marketing materials implying current availability become inaccurate

Wind-down period (varies, typically 60–180 days):

• The FDA may issue guidance allowing dispensing of inventory already prepared before the effective date
• Prescriptions already in process may be handled differently depending on the specific guidance
• Outsourcing facilities typically receive longer wind-down windows than 503A pharmacies

After wind-down:

• Any further compounding or marketing for patient use is a violation of FDCA
• The compound transitions to RUO status only (if the FDA does not flag additional safety concerns that would restrict even that)

For BPC-157 and TB-500 specifically: given the clinical following these compounds have developed and the volume of practitioner nominations, any Category 3 determination would likely be phased with a comment period and wind-down. But “likely phased” is not a compliance strategy. Brands should develop contingency communications now that accurately inform patients and providers about the possibility of status change.

International Regulatory Comparison

The US 503A/503B framework is specific to the FDCA, but analogous structures exist internationally.

European Union: Compounding (called “magistral preparation”) is regulated at the member-state level with no centralized EU equivalent to the 503A Bulks List. EMA has no direct oversight of compounding pharmacies. Individual countries (Germany, Netherlands, Belgium) have national lists of permitted magistral substances. Most peptides legally compounded in the US do not have equivalent authorization in major EU markets.

Canada: Health Canada administers compounding pharmacy regulation through provincial pharmacy regulators, with a centralized list of permitted bulk substances maintained by Health Canada. Several peptides in Category 1 under FDA 503A have approved pathways in Canada; some Category 2 compounds do not. Canadian pharmacy platforms marketing to US patients, or vice versa, face jurisdiction issues that require careful legal review.

Australia: The Therapeutic Goods Administration (TGA) regulates compounding under Section 24 of the Therapeutic Goods Act. Australia’s Special Access Scheme (SAS) and Authorised Prescriber pathway create mechanisms for some compounds not otherwise registered. Several peptides face TGA-specific restrictions.

Operational implication: International sourcing of bulk peptide APIs does not cure US regulatory issues. A peptide legally manufactured and sold in China or Germany is not thereby permissible for compounding in a US 503A pharmacy without FDA approval of the substance.

Compliance Guidelines for Advertising Compounded Peptides

Advertising compounded medications is subject to a distinct set of rules from advertising supplements or research chemicals. The key requirements:

Prescription Requirement Disclosure

Compounded peptide medications require a valid prescription from a licensed provider. All marketing must make this clear. Implying patients can obtain compounded peptides without a prescription is both inaccurate and creates regulatory exposure.

No Comparative Efficacy Claims Against FDA-Approved Drugs

Compounded products cannot be marketed as equivalent to or better than FDA-approved medications. This is particularly relevant for peptides that have approved analogs — Tesamorelin/Egrifta or PT-141/Vyleesi are examples where the compounded version may not be marketed as equivalent.

The statutory basis for this prohibition operates on two independent tracks. First, FDCA Section 502 misbranding: A drug is misbranded under Section 502(a) if its labeling is “false or misleading in any particular.” Marketing a compounded preparation as equivalent to an FDA-approved drug implies that it has demonstrated pharmacokinetic equivalence, consistent bioavailability, and the same clinical performance — none of which a compounded preparation has undergone. For a generic drug to make a therapeutic equivalence claim, the manufacturer must complete an Abbreviated New Drug Application (ANDA) under 21 U.S.C. § 505(j), submitting pharmacokinetic bioequivalence studies demonstrating that the test product’s AUC and Cmax fall within 80–125% of the reference listed drug under standardized conditions. A compounding pharmacy holds no 505(j) approval; its preparations lack the batch-to-batch potency verification and pharmacokinetic characterization that underpins any equivalence claim. Marketing language stating the compounded version delivers equivalent clinical outcomes is therefore a false or misleading labeling statement that satisfies the Section 502(a) misbranding definition — subjecting the pharmacy and its marketing partners to FDCA Section 301(a) enforcement exposure. Second, equivalence claims self-defeat the compounding exemption: The 503A framework permits compounding a commercially available RLD only when the prescriber documents patient-specific clinical need the approved product cannot meet — a different concentration, a required formulation change, or a clinically necessary excipient substitution. A marketing statement claiming that the compounded preparation is equivalent to, say, Egrifta is structurally self-defeating: if the compounded version delivers equivalent clinical outcomes, there is no clinical gap the approved product fails to fill, and the legal basis for compounding it under 503A evaporates. Sophisticated legal review of any comparative language is essential — claims intended to build prescriber confidence in product quality can simultaneously undermine the regulatory justification for producing the product at all.

Substantiated Claims Only

Health claims must be substantiated by competent and reliable scientific evidence before they appear in advertising. The legal standard is more specific than it might appear. Under FTC Act Section 5, which prohibits “unfair or deceptive acts or practices,” the FTC has operationalized its health claim substantiation requirement through a series of consent orders that define “competent and reliable scientific evidence” as: tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results. The FTC’s 2022 Health Products Compliance Guidance (updated from the 1998 guidance) refines this into an evidence hierarchy: for claims about effects on human health or function, randomized, adequately controlled human trials are the expected evidentiary standard where “feasible” — and the FTC’s position is that feasibility is determined by whether the intervention has reached a stage where human trials are scientifically appropriate, not by whether a company has chosen to fund them. Animal studies and in vitro data can inform biological plausibility but do not independently satisfy the competent-and-reliable standard for claims about human therapeutic outcomes. The FTC’s position, applied to the typical format of peptide marketing claims, maps as follows: “promotes tissue healing” or “accelerates recovery” as human-use claims require human RCT evidence; “has been studied for its effects on angiogenesis in animal models” is an accurately qualified research statement that does not assert a human clinical outcome. For BPC-157 and TB-500 specifically, the entire published evidence base — however mechanistically interesting — is preclinical. Under the FTC’s current guidance, using this preclinical literature to support unqualified human outcome claims constitutes a substantiation failure under Section 5, creating deceptive advertising liability for the marketer independent of the FDA regulatory compliance question.

State-Specific Rules Apply

State boards of pharmacy regulate compounding pharmacies. Several states have additional restrictions on advertising compounded preparations beyond federal requirements. Multi-state operators need legal review of marketing materials in each jurisdiction of operation.

FTC Endorsement Rules

Patient testimonials for prescription products are subject to FTC guidance on testimonials and endorsements, including disclosure of material connections and representation of typical results. The FTC’s 2023 update to the Endorsement Guides increased scrutiny on testimonials that imply typical consumer results. Testimonials about compounded peptide outcomes should include clear disclosure of individual variation and medical oversight.

Off-Label Use Communication

Many compounded peptides are prescribed for off-label uses — uses beyond whatever approved indication exists for the analogous drug (if any). Off-label prescribing is legal for physicians but promotional activity for off-label uses by manufacturers or compounders is restricted. Marketing that encourages off-label use of compounded preparations should be reviewed by legal counsel against FDCA off-label promotion standards.

Marketing Strategy by Category

For Category 1 Peptides: Invest with Confidence

Regulatory stability supports longer-term brand investment. Marketing can develop deep clinical content around Sermorelin, Ipamorelin/CJC-1295, and PT-141 because these compounds’ compounding eligibility is determined, not pending. SEO content, educational guides, patient decision-aid materials, and provider education programs are all reasonable investments.

Emphasize the prescription-based, medically supervised nature of access — this is both accurate and a meaningful differentiator from unregulated research chemical suppliers.

For Category 2 Peptides: Accurate Communication and Scenario Planning

Marketing should be accurate about current status without implying permanence. Patients and providers asking about BPC-157 deserve honest communication about what Category 2 means: legally compoundable now, pending a final FDA determination. Build content that can be updated rapidly if status changes. Avoid deep infrastructure investments (custom platforms, branded programs built entirely around a single Category 2 compound) without a contingency plan.

Monitor the FDA public dockets for PCAC meeting schedules that might indicate upcoming decisions on BPC-157, TB-500, or other Category 2 peptides of commercial interest.

For Category 3 Peptides: Clear Boundaries

Do not create marketing materials that imply these are available through legitimate compounding channels. This protects you, your clients, and their patients. Research-use framing may be appropriate for educational content about mechanisms, but must be accompanied by clear disclosure that these compounds are not available through licensed compounding pharmacies for patient use.

Staying Current as the Landscape Changes

The peptide compounding regulatory environment in 2026 is more defined than it was in 2023–2024, but it is not static. The FDA continues to process Category 2 nominations, the GLP-1 compounding enforcement demonstrated how quickly shortage-based exceptions can close, and legislative changes (including proposed reforms to FDCA compounding provisions) could alter the framework further.

Brands investing in peptide marketing now should build content and positioning strategies that can adapt to changing classification status. The brands that navigate this environment best communicate accurately with their audiences, monitor regulatory developments through FDA public dockets and PCAC meeting notices, and work with legal and marketing teams that understand the specific framework governing each compound.

---

Regulatory Sources

1. U.S. Food and Drug Administration. Bulk Drug Substances That May Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov
2. U.S. Food and Drug Administration. Human Drug Compounding — Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov
3. U.S. Food and Drug Administration. Drug Shortage Database. FDA.gov
4. Federal Trade Commission. FTC’s Endorsement Guides: What People Are Asking. FTC.gov
5. Gudeman J, et al. Potential Risks of Pharmacy Compounding. Drugs R D. 2013;13(1):1–8. PMID:23322302
6. Allen LV Jr. Section 503A and 503B of the Drug Quality and Security Act: What Does It Mean for Pharmacy Compounding? Int J Pharm Compd. 2014;18(2):106–108.

---

For related reading: Peptide Market Industry Landscape 2026 · Peptide Pipeline: Clinical Trials to Watch in 2026 · BPC-157: Pain Relief, Oral vs. Injectable Guide · TB-500 Thymosin Beta-4 Research Guide · GHK-Cu Copper Peptide Guide